02
JUN
2020
NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
Comments : Off
BETHESDA, Md., June 2, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer. The Company reported that the final data collection process has been progressing steadily despite ongoing difficulties due to coronavirus-related... Read More